Temab-A plus bevacizumab: 30% response rate and 14.7-month median survival in a 30-patient Phase 1 colorectal cancer study; ...

The Madrid congress begins Oct. 23, with updated lung cancer data, initial prostate cancer combination data and preliminary ...

The interim analysis included 48 Cyclin E1-positive and 46 negative patients; no new safety signals were observed. A rapid ...

Of patients whose plans changed, 87% had treatment de-escalated based on negative MRD results; the assay detected ctDNA ...

Study 304 tested VDPHL01 at 8.5 mg once and twice daily against placebo; the live webcast is set for 8 a.m. ET, with slides ...

Raises Serious Questions About Board Credibility Following Inaccurate Financial Claims and Mischaracterizations of Mr.

Dawn will chair Private Capital Advisory, Nataraj will keep advising clients, and Daniel Mendelow will become sole head of U.S. investment banking.

Two investigational therapies are in ongoing Phase 3 programs; Incyte will discuss ESMO data and portfolio updates at an Oct.

Stock market news for October 18, 2026. Press releases, financial news, and business developments from public companies with ...

The 48-cell version delivers a maximum 510 W and about 30 W more power than conventional back-contact modules; its ...

A study of 9,938 surgical cases found improved depth and frequency of assessment versus manual activation; savings came from ...

Retirement savings by age in the Fed's newest survey, released October 2026: median balances, who has no account, and how many families reach the 10x rule.